Creative Planning
EDIT icon

Creative Planning’s Editas Medicine EDIT Stock Holding History

Creative Planning’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500
Closed -$18K – 2629
2020
Q4 		$18K Hold
500
– – ﹤0.01% 2193
2020
Q3 		$2K Buy
+500
New +$16.3K ﹤0.01% 2091

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Creative Planning's EDIT Position: Q2 2026 in Review

Creative Planning increased its Editas Medicine (EDIT) stake by 97% in Q2 2026, buying an estimated $65.7K and bringing the position to 45,572 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #3966.

Creative Planning first reported a position in EDIT in Q1 2016 and has held it in 27 quarters since. The position peaked at $1.5M in Q4 2019. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Creative Planning held 45,572 shares of Editas Medicine worth $148K as of Q2 2026.
  • Creative Planning bought 22,488 Editas Medicine shares in Q2 2026, an estimated $65.7K.
  • Editas Medicine made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3966 holding.
  • Creative Planning first reported a position in Editas Medicine in Q1 2016 and has held it in 27 quarters since.
  • Creative Planning's Editas Medicine position peaked at $1.5M in Q4 2019.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.